OFOlivia Foley

Olivia Foley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olivia Foley has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trends in opioid-, alcohol-, and drug-related mortality among US children aged 0–4 years: an analysis of the CDC WONDER Database trends, 1999–2023

    by Taryn Geiger, Roxana Shahmohammadi Arani, Kennedy Haase, Olivia Anne Foley, Abubakar Tauseef

    Over the past two decades, the USA has observed fluctuating increases in opioid-, alcohol-, and drug-related mortality amongst children under the age of 4. Many factors contribute to mortality, and identifying preventative measures represents a critical gap in public health. This study aims to identify trends in related deaths and highlight potential target areas to combat mortality increases. Data was extracted from the Center for Disease Control and Prevention Wide-ranging Online data for Epidemiologic Research (CDC WONDER) database, and trends in crude mortality rate were analyzed for children ages 0–4 from 1999 to 2023. Results were stratified according to sex, region, race, and age; trends were assessed utilizing Joinpoint analysis software. Overall, crude mortality rates demonstrated an upward trend. Across every census region, there was an increase in mortality, noting the highest in the Midwest region. In nearly every year, rural regions are noted to have a higher crude mortality rate. Male sex was associated with a higher crude mortality rate, and the Non-Hispanic Black or African American population had the largest increase in crude mortality rate compared to other racial/ethnic groups. Conclusion : Complex factors contribute to mortality in this population, with clear disparities across geographic locations and demographic groups. These disparities highlight the need for further exploration regarding the effects of the opioid epidemic in the pediatric population. Integrating preventative measures and educational tools into medical education and healthcare systems across the country represents a notable absence in current practice, and direction for future research.

  • Open Access

    Understanding mortality trends in patients with uterine malignancies from 1999 to 2023 utilizing the CDC WONDER database

    by Shannon Blee, Sun Young Guwn, Olivia Foley, Taylor Billion, Peter Silberstein, Abubakar Tauseef

    Blee S, et al. J Gynecol Oncol. 2026 ;37:e143. https://doi.org/10.3802/jgo.2026.37.e143

  • Open Access

    Racial and Ethnic Differences in Trial of Labor After Cesarean Attempts and Vaginal Birth After Cesarean Success Rates: A Retrospective Single-Health System Study

    by Olivia Foley, Shannon Blee, Rebecca Hammond, Kallin Hermann, Claire Malhotra, Danielle B. Dilsaver, Megan Kalata


  • Understanding and addressing bias in urine drug screening protocols on high-volume labor and delivery units

    by Megan Kalata, G. Sotolongo, L. Ahlers, L. Byrne, O. Doll, O. Foley, G. Folino, K. Hermann, M. Maglasang, N. Perme, et al.

    Background: The purpose of this study was to understand the current demographics and characteristics of patients undergoing urine drug screening on labor and delivery units with the intention of using this data to create a more evidence-based, equitable policy to reduce bias in the screening process. Methods: A retrospective chart review was performed of 509 instances of drug screening occurring for pregnant and recently delivered patients across three hospitals in Omaha, Nebraska. Demographics of patients, including age, race, ethnicity, and insurance status, as well as reasons for drug screening, patient consent, screening results, and disclosure of results, were analyzed to assess patterns in screening. Results: 509 screening instances were evaluated with 324 unique patients. While Black patients made up 11.6% of the overall patient population, they accounted for 26.2% of the patients undergoing urine drug screenings. 2.88% of all patients self-identified as Hispanic; however, they comprised 13.4% of all patients screened. Consent was documented in 11.3% of cases and a reason for obtaining UDS was documented in 61.5% of cases. The most common reasons cited were history of substance use or current use, medical indications, and suspected use without documented history of use. Conclusions: Establishment of more specific, evidence-based policies for urine drug screening may reduce the impact of implicit biases on current screening practices and serve as one avenue to rebuild trust with patients who have historically been marginalized by the medical community.